I guess that using a database of pharmaceutical drug injury is completely outrageous, how can you assume that the deaths are really caused by the vaccines.
It's all about the rare cases of death from happiness of being vaccinated...
30 years and 70 different vaccines did produce much less death than 6 months Pfizer/Astra/ Moderna...
Conclusion:: Old - classic vaccines don't make you happy!
and to be honest I thought it was late.
The problem is that it went through peer review..and the math logic is clear
Is the 'Concern' a kneejerk reaction to placate the screams from the vaccine zealots?
The present assessment raises the question whether it would be necessary to rethink policies and use COVID-19 vaccines more sparingly and with some discretion only in those that are willing to accept the risk because they feel more at risk from the true infection than the mock infection.
Perhaps it might be necessary to dampen the enthusiasm by sober facts?
In our view, the EMA and national authorities should instigate a safety review into the safety database of COVID-19 vaccines and governments should carefully consider their policies in light of these data.
Ideally, independent scientists should carry out thorough case reviews of the very severe cases, so that there can be evidence-based recommendations on who is likely to benefit from a SARS-CoV2 vaccination and who is in danger of suffering from side effects.
Currently, our estimates show that we have to accept four fatal and 16 serious side effects per 100,000 vaccinations in order to save the lives of 2–11 individuals per 100,000 vaccinations, placing risks and benefits on the same order of magnitude.
Display MoreThe problem is that it went through peer review..and the math logic is clear
Is the 'Concern' a kneejerk reaction to placate the screams from the vaccine zealots?
Conclusions
The present assessment raises the question whether it would be necessary to rethink policies and use COVID-19 vaccines more sparingly and with some discretion only in those that are willing to accept the risk because they feel more at risk from the true infection than the mock infection.
Perhaps it might be necessary to dampen the enthusiasm by sober facts?
In our view, the EMA and national authorities should instigate a safety review into the safety database of COVID-19 vaccines and governments should carefully consider their policies in light of these data.
Ideally, independent scientists should carry out thorough case reviews of the very severe cases, so that there can be evidence-based recommendations on who is likely to benefit from a SARS-CoV2 vaccination and who is in danger of suffering from side effects.
Currently, our estimates show that we have to accept four fatal and 16 serious side effects per 100,000 vaccinations in order to save the lives of 2–11 individuals per 100,000 vaccinations, placing risks and benefits on the same order of magnitude.
You said it more politely RobertBryant , the "notice of concern" must have come after this paper went viral on the so called "social networks" and the Journal Editor was forced to put the notice to quench the fire.
Conclusion:: Old - classic vaccines don't make you happy!
The current vaccinated generation in rich countries will receive 12 vaccines at least
if they live out their healthy lifespan in their pursuit of happiness...
https://www.health.gov.au/site…n-indigenous-people_0.pdf
These 12 vaccines.. have a much less happy road to approval than
the relatively free pass for the current Covid vaccines,
I may forgo the shingles vaccine..
"70–79 years • Shingles (herpes zoster) Zostavax®
I will take oral ivermectin instead.. currently there does not seem to be a patent on its use.
except maybe as lotion..
"
0070 A 63 year-old male presented with a five day history of shingles in a band on the skin of his left thorax at the level of T-8 and 9. The patient had severe pain with burning and tingling that had not responded to high dose of Famvir R.
The patient was then treated with CompositionA of the ivermectin lotion of Example 1 one to two times a day.
All persistent vesicles and pustules were decapitated first to allow penetration of the lotion into the lesions,
and then the ivermectin lotion is rubbed on the affected area.
This afforded immediate relief of the severe pain and the steady healing of the damaged skin.https://patentimages.storage.g…302f2/US20130172282A1.pdf
Good signs of a long (life-long??) persistence of Antibodies after mRNA vaccination?? Would avoid unnessary shots...
It is also expected (verfied?) that having undergone a completed Covid-19 Infection you might have the same immune response in the end, when you are exposed to the virus and its variants again.
Anybody has an idea (or are there reports?), how the immune system may react or change or stop the production of Antibodies, T-Cell responses etc., if the infection (e.g. with mild to light-severe symptoms) is treated / "stopped" with the "known" medication (e.g. Ivermectin). Will the body end up having the same immune repsonse later on in those patients vs the one that fully run through a Covid-19 infection and recovered?
Drug repurposing based on a Quantum-Inspired method versus classical fingerprinting uncovers potential antivirals against SARS-CoV-2 including vitamin B12
https://www.biorxiv.org/conten…/2021.06.25.449609v1.full
Abstract
The COVID-19 pandemic has accelerated the need to identify new therapeutics at pace, including through drug repurposing. We employed a Quadratic Unbounded Binary Optimization (QUBO) model, to search for compounds similar to Remdesivir (RDV), the only antiviral against SARS-CoV-2 currently approved for human use, using a quantum-inspired device. We modelled RDV and compounds present in the DrugBank database as graphs, established the optimal parameters in our algorithm and resolved the Maximum Weighted Independent Set problem within the conflict graph generated. We also employed a traditional Tanimoto fingerprint model. The two methods yielded different lists of compounds, with some overlap. While GS-6620 was the top compound predicted by both models, the QUBO model predicted BMS-986094 as second best. The Tanimoto model predicted different forms of cobalamin, also known as vitamin B12. We then determined the half maximal inhibitory concentration (IC50) values in cell culture models of SARS-CoV-2 infection and assessed cytotoxicity. Lastly, we demonstrated efficacy against several variants including SARS-CoV-2 Strain England 2 (England 02/2020/407073), B.1.1.7 (Alpha), B.1.351 (Beta) and B.1.617.2 (Delta). Our data reveal that BMS-986094 and different forms of vitamin B12 are effective at inhibiting replication of all these variants of SARS-CoV-2. While BMS-986094 can cause secondary effects in humans as established by phase II trials, these findings suggest that vitamin B12 deserves consideration as a SARS-CoV-2 antiviral, particularly given its extended use and lack of toxicity in humans, and its availability and affordability. Our screening method can be employed in future searches for novel pharmacologic inhibitors, thus providing an approach for accelerating drug deployment
Discussion
We present a QUBO model employing the quantum-inspired device Fujitsu’s Digital Annealer19 and a classical method based on fingerprints, Tanimoto measure15, to seek compounds structurally similar to RDV in the DrugBank database (Figure 1a). We demonstrated how both approaches identified compounds that showed antiviral properties in vitro in two cell culture models (Figures 2-5). Our QUBO model rendered BMS-986094 as the second-best candidate (Table 5), which was proven to inhibit viral replication of several variants of SARS-CoV-2 (Figure 5). Importantly, we demonstrated that several forms of vitamin B12, namely cobamamide (adenosylcobalamin), methylcobalamin and hydroxocobalamin, currently used worldwide both orally and intravenously, inhibited replication of several variants of SARS-CoV-2 in vitro (Figure 5). Although animal models are required to determine whether these effects can be seen in vivo, there are already several studies investigating the possible relationship between vitamin B12 levels and SARS-CoV-2 infection outcome.26,27
Our approach to solve a MIS problem has been implemented in other settings. Chemical similarity approaches have their pitfalls: errors in chemical structures as well as physiological effects that exist beyond the structural relationship (for example, a metabolite of the original drug with a modified structure could be the active molecule) could limit the use of this approach in drug repurposing.28 For example, Bollobás et al29 used MIS to help solve the Graph Coloring Problem. The authors extracted the maximal independent set of uncolored vertices iteratively to assign them the same color, repeating the process until the whole graph is colored. A similar technique was followed by Johnson19, where several independent sets were first constructed and then a new color class selected after removing one of them with the smallest edge density. The algorithm repeated this process until a threshold number of uncolored vertices were left. After that, an exhaustive search algorithm was applied to color those remaining vertices. This problem was solved using several metaheuristics, such as Simulated Annealing20, Tabu Search30, GRASP31, or Genetic and Hybrid Algorithms.32 More recent studies included efficient ways based on fast local search procedures to produce near-optimal solutions to a wide variety of instances.33 Jin et al. presented a general Swap-Based Local Search method based on Tabu Search to obtain the best-known solutions for two well-known set of instances used to evaluate algorithms. 34
Regarding the MWIS problem, one can implement a Genetic Algorithm35, involving a two-fusion crossover operator and a mutation operator that is replaced by a heuristic-feasibility operator. The first operator considers both the structure and the fitness of two parent solutions to produce two children. The second one transforms infeasible solutions into feasible ones, with these being able to run in parallel. These problems involve determining DNA and amino acid sequence similarity and were reported by Joseph et al.36 The authors proposed an algorithm that ran in O(n log n) computational time. With regards to QUBO, a more detailed description about how to formulate problems in this special mathematical way is described by Glover et al.37
Recent studies showed the use of QUBO models to formulate the MIS problem to be solved by a Quantum Annealer. Similarity among a set of molecules has been implemented by relaxing the definition of measure by using the Maximum Co-k-plex relaxation method38, a more general form of describing the MIS problem. Hernandez et al39 reported that molecular similarity methods can take advantage of Quantum Annealers. The authors considered different relevant pharmacophore features to describe the molecules for ligand-based virtual screening, including atomic coordinates as features for comparison. The results showed better performance than fingerprint methods for most of the datasets used. Several attempts to solve combinatorial optimization problems with Fujitsu Digital Annealer were reported by Aramon et al40and Hong et al.41 With regards to the choice of parameters for our QUBO model, we considered that the δ parameter value being 0 only described the nature of the instances and that similarity values had very different outcomes comparing the results from the experts from the ones given by the model.
Our data showed that the distribution of similarity values differed between the QUBO model vs the Tanimoto measure (Figure 1b, Tables 5 and 6), indicating that we could not directly compare solutions given by each method. Solutions that are good for one method may not be so in the other. Our experiments demonstrated that both approaches can discover potential antiviral compounds and that both models should be run in parallel (Figures 2-5). Solutions to the models (drug targets) produced in both cases can be very useful in different settings and show different properties in humans. BMS appeared to be a better candidate for SARS-CoV-2 replication inhibition (Figures 2-5) than vitamin 12 when we compared side-by-side IC50 concentrations. Previous studies have observed harmful cardiac effects, which halted its progression from phase II clinical trials.42 The dose administered in the trial was 100mg orally (clinical trial NCT01629732). Our estimated IC50 of 26.6μM is higher than the established EC50 of 10nM for BMS in hepatitis C virus (HCV) infection43, but further studies would be required to establish bioavailability in mucosae.
Our data demonstrated that several forms of vitamin B12 inhibit SARS-CoV-2 replication in vitro in two different cell lines (Figures 3-5). In humans, injections of up to 10mg have not shown side effects. The healthy range of vitamin B12 in blood is 118-701 pM. Vitamin B12 deficiency is treated with injections of 1mg hydroxocobalamin44, with 1mg/mL hydroxocobalamin being 742.2μM. Higher doses of hydroxocobalamin are however tolerated. Upon cyanide poisoning, adults can receive up to 5g of hydroxocobalamin as an antidote intravenously, which would be well within the range of our calculated IC50 of 403μM. Moreover, previous studies on imaging show biodistribution of an intravenous In-111 labeled 5-deoxyadenosylcobalamin (AC) analog ([111In]AC) in nasal cavity and salivary glands45. There is also previous evidence of vitamin B12 having potential antiviral effects. An in silico screening by Narayanan and Nair46 showed their second best docking score between methylcobalamin and nsp12 (the gene that encodes for RdRP). Vitamin B12 has been shown to improve outcome in hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that has an internal ribosomal entry site (IRES) which interacts with cellular ribosomal subunits, and vitamin B12 has been reported to work by inhibiting HCV IRES-dependent translation. 47 Interestingly, BMS was originally designed against HCV.48
Our findings open the door to employing Quantum-inspired methods to inform drug repurposing. Our data showed novel compounds that were able to inhibit SARS-CoV-2 replication based on our QUBO model as well as the more traditional Tanimoto fingerprint, such as BMS and cobalamin derivatives. BMS warrants further investigation, while vitamin B12 is readily available from multiple sources, it is affordable, can be self-administered by patients, is available worldwide, and displays low-to-no toxicity at high doses.
Pittsburgh man dies after 2nd Moderna dose, doctors say, in first known blood clotting case linked to the vaccine
https://www.rt.com/usa/527823-…a-vaccine-blood-clot/amp/
Doctors in Pennsylvania have reported the first known case of severe blood clotting believed to be linked to Moderna’s coronavirus vaccine, after an elderly man contracted the condition and died within days of his second dose.
Healthcare professionals at the Allegheny Health Network in Pittsburgh reported the case on Monday, noting that a 65-year-old man arrived at the hospital with a serious form of blood clotting known as thrombosis with thrombocytopenia (TTS) just 10 days after his second and final dose of the Moderna shot. Two days later, the unnamed patient, who also suffered from chronic hypertension and high cholesterol levels, died, with doctors concluding his symptoms were consistent with vaccine-induced clotting, also known as VITT.
“The distribution of thrombosis, especially the cerebral venous sinus thrombosis, was characteristic of VITT or TTS,” the doctors wrote in a journal article published at the Annals of Internal Medicine.
They said their findings “fulfill the interim case definition of VITT or TTS” set out by the CDC and that further blood tests “[strengthened] the likelihood” of a vaccine-linked condition. However, while they called their evidence for VITT “robust,” the doctors cautioned that they could not rule out other causes for the clotting.
The report in Pittsburgh would be the first known case of blood clotting linked to a vaccine based on messenger RNA, or genetic material located in the cell, which includes those developed by Moderna and Pfizer. While a number of recipients of the AstraZeneca and Johnson & Johnson shots have developed clotting, including some fatal cases, those vaccines use different technology and are instead based on a deactivated adenovirus.
The doctors at Allegheny Health said their research “complicates” theories that prior clotting cases were specifically caused by adenovirus-based vaccines, as some experts have previously speculated.
While adverse reactions have remained uncommon among the millions of vaccine recipients in the US, clotting is not the only vaccine-related condition to crop up. Last week, the CDC reported more than 1,200 cases of a rare disorder known as myocarditis, or inflammation of the heart, in those who took the Pfizer and Moderna shots, which comes to about 12.6 per million doses. The health body found a “likely association” between the vaccines and the condition, though noted it is “still a rare event.”
Ongoing clotting complications with the AstraZeneca and J&J inoculations have also prompted some countries to put the shots on hold, with Denmark opting to continue its suspension last Friday. Though the AstraZeneca formulation has yet to be approved in the US, American health officials previously paused the J&J shot over safety concerns, but resumed its rollout in April.
While the doctors in Pittsburgh may have discovered the first clotting case linked to an mRNA vaccine, they noted that “many millions” had received such immunizations without serious side effects, adding that their report “should not prevent persons from receiving the benefits of these vaccines.”
Why most people who now die with Covid in England have had a vaccination
https://amp.theguardian.com/th…ovid-have-been-vaccinated
A MailOnline headline on 13 June read: “Study shows 29% of the 42 people who have died after catching the new strain had BOTH vaccinations.” In Public Health England’s technical briefing on 25 June, that figure had risen to 43% (50 of 117), with the majority (60%) having received at least one dose.
It could sound worrying that the majority of people dying in England with the now-dominant Delta (B.1.617.2) variant have been vaccinated. Does this mean the vaccines are ineffective? Far from it, it’s what we would expect from an effective but imperfect vaccine, a risk profile that varies hugely by age and the way the vaccines have been rolled out.
Consider the hypothetical world where absolutely everyone had received a less than perfect vaccine. Although the death rate would be low, everyone who died would have been fully vaccinated.
The vaccines are not perfect. PHE estimates two-dose effectiveness against hospital admission with the Delta infections at around 94%. We can perhaps assume there is at least 95% protection against Covid-19 death, which means the lethal risk is reduced to less than a twentieth of its usual value.
But the risk of dying from Covid-19 is extraordinarily dependent on age: it halves for each six to seven year age gap. This means that someone aged 80 who is fully vaccinated essentially takes on the risk of an unvaccinated person of around 50 – much lower, but still not nothing, and so we can expect some deaths.
The PHE report also reveals that nearly a third of deaths from the Delta variant are of unvaccinated people over 50, which may be surprising given high vaccine coverage; for example, OpenSAFELY estimates more than 93% among the 65-69s. But there are lower rates in deprived areas and for some ethnicities and communities with limited coverage will continue to experience more than their fair share of loss.
Coverage and effectiveness are important numbers for assessing vaccination programmes. It is better to look at cool analysis by analysts, rather than hot takes on social and other media.
David Spiegelhalter is chair of the Winton Centre for Risk and Evidence Communication at Cambridge. Anthony Masters is statistical ambassador for the Royal Statistical Society
Dating first cases of COVID-19
https://journals.plos.org/plos…1371/journal.ppat.1009620
Abstract
Questions persist as to the origin of the COVID-19 pandemic. Evidence is building that its origin as a zoonotic spillover occurred prior to the officially accepted timing of early December, 2019. Here we provide novel methods to date the origin of COVID-19 cases. We show that six countries had exceptionally early cases, unlikely to represent part of their main case series. The model suggests a likely timing of the first case of COVID-19 in China as November 17 (95% CI October 4). Origination dates are discussed for the first five countries outside China and each continent. Results infer that SARS-CoV-2 emerged in China in early October to mid-November, and by January, had spread globally. This suggests an earlier and more rapid timeline of spread. Our study provides new approaches for estimating dates of the arrival of infectious diseases based on small samples that can be applied to many epidemiological situations.
Author summary
While the COVID-19 pandemic continues, questions still persist as to its origins. Evidence is building that its origin as a zoonotic spillover occurred before the officially accepted timing of early December, 2019. We date the origin of COVID-19 cases from 203 countries and territories using a model from conservation science. We use a method that was originally developed to date the timing of extinction, and turn it to date the timing of origination using case dates rather than sighting events. Our results suggest that the virus emerged in China in early October to mid-November, 2019 (the most likely date being November 17), and by January, 2020, had spread globally. This suggests a much earlier and more rapid spread than is evident from confirmed cases. In addition, our study provides a new approach for estimating dates of the arrival of infectious diseases in new areas that can be applied to many different situations in the future.
Discussion
While the first case of COVID-19 was officially identified in early December, 2019 [1], it is likely that SARS-CoV-2 had spilled over into humans much earlier. Nsoesie et al. [3] identified significant changes in hospital and search engine traffic in Wuhan during August to October, 2019, suggesting a possible earlier existence of COVID-19. The recent joint WHO-China study on the global origin of SARS-CoV-2 found that, based on a review of molecular evidence, most point estimates place the most recent ancestor at between mid-November and early December, with a range from late September to early December [5]. Our results support the existing evidence and suggest that the first case of COVID-19 would have been sometime between early October and mid-November. Further, our results suggest the most likely timing of the first case to be November 17, 2019.
Expanding this comparison to four other studies that identified earlier cases, we inferred January 7, 2020 (95% CI December 22, 2019) as the most likely first case in Thailand. This is only 1 day after a case identified in a traveller to Thailand from Wuhan on January 8, 2020 [15,16]. However, the most likely first case in France was inferred as January 19, 2020 (95% CI January 4, 2020), while a retrospective review of medical records identified one patient as having COVID-19 from December 27 [6]. This is eight days earlier than our inferred 95% CI. Similarly, from an analysis of 40 composite influent wastewater samples from northern Italy, La Rosa et al. [17] detected SARS-CoV-2 in samples collected on December 18, 2019, over six weeks before the first confirmed case on January 31, 2020. In our analysis we removed this first case (January 31, 2020) as it was significantly divergent in terms of timing from the rest of the cases, resulting in an inferred first case of February 20, 2020 (95% CI February 16, 2020). However, if this first case is retained then it pushes back our inferred first case to January 1, 2020 (95% CI August 10, 2019), which is more in line with the findings of La Rosa et al. [17]. In contrast, our analysis pushed back the most likely first case in the United States to mid-January (January 16, 2020; 95% CI January 3, 2020), two weeks prior to the earliest known case of a woman identified through retrospective testing who became ill on January 31, 2020, and almost 6 weeks before the first recognised case on February 26 [7]. Further analysis of retrospective testing studies will help validate the application of OLE and associated methods.
Using the method of Solow and Smith [14], we identified six countries with exceptionally early cases of COVID-19 compared with the rest of the case time series for those countries. These may represent isolated cases, infections that did not contribute to the eventual spread of COVID-19 through the country or territory. However, currently only the results of retrospective testing have been published for Italy as described above. Without such analyses it is not possible to determine if our results have in fact identified early isolated cases or simply reflect poor surveillance and pre-symptomatic transmission.
In the same way the extinction events are rarely observed, so too are origination events such as those of COVID-19. Without rigorous tracing systems, dating the first cases has to be inferred. In the case of emerging infectious diseases, this is most frequently based on phylogenetic analysis. For this to be meaningful, it requires sufficient sampling and diversity. Here we applied a well-established extinction estimator (i.e. OLE) from conservation science, to estimate the origination times of COVID-19 for all countries with five or more case dates. As the method can be effectively applied to very sparse datasets, with as few as 4–5 records [18,19], it illustrates the potential to rapidly gain an understanding of the origination timings of novel zoonotic diseases when they are poorly known. Moreover, some of the approaches from this group of methods can be applied even to records with just two [20] or even a single record [21]. Using methods borrowed from conservation science, we are able to estimate a range of likely dates for the zoonotic spillover of COVID-19 into humans in China and the subsequent spread to countries around the world.
Some more Covid news from Canada.
My city of Toronto has set a world record. On Sunday we opened up the Air Canada Centre (now called ScotiaBank Centre where the Toronto Maple Leafs and Toronto Raptors play), and amid lots of fanfare we vaccinated over 26,000 people. That's the most ever in one place in one day, worldwide.
Have to hand it to those who came up with this idea. Keep people out of popular sports venues for over a year, and then open the floodgates for a one time celebratory mass vaccination event! Genius.
***********
Some researchers were suspicious of Canada's exceptionally high proportion of covid deaths in long term care homes relative to overall covid deaths : 80 percent. They now write that Covid deaths outside of care homes have been under reported by at least 66 percent! If this under reporting has continued to the present, it means that reported Canada's Covid deaths may be half of the real number. Close enough for government work?
Display MoreSome more Covid news from Canada.
My city of Toronto has set a world record. On Sunday we opened up the Air Canada Centre (now called ScotiaBank Centre where the Toronto Maple Leafs and Toronto Raptors play), and amid lots of fanfare we vaccinated over 26,000 people. That's the most ever in one place in one day, worldwide.
Have to hand it to those who came up with this idea. Keep people out of popular sports venues for over a year, and then open the floodgates for a one time celebratory mass vaccination event! Genius.
***********
Some researchers were suspicious of Canada's exceptionally high proportion of covid deaths in long term care homes relative to overall covid deaths : 80 percent. They now write that Covid deaths outside of care homes have been under reported by at least 66 percent! If this under reporting has continued to the present, it means that reported Canada's Covid deaths may be half of the real number. Close enough for government work?
I guess that no early treatment and quarantine in place has had some problems up there. I wonder when that policy will be reviewed
This is available only in Spanish for now, but a vial of Corminaty (tm) Pfizer vaccine was analyzed and it is confirmed to contain Graphene flakes. This would contribute to explain the induced electromagnetic properties observed by many but still officially denied.
One reason why it is good idea to have at least a sizeable minority unvaccinated : If the minority is too small, they will get bulldozed and bullied because their numbers are too small to resist increasingly autocratic leadership, if they ever could anyway. My bold :
DUBAI, United Arab Emirates — Abu Dhabi, the oil-rich capital of the United Arab Emirates, has announced that a wide range of public places will soon be accessible only to those vaccinated against the coronavirus in a bid to encourage more people to get shots.
The Emirati government on Monday said that starting August 20, authorities will begin restricting access to shopping malls, restaurants, cafes, sporting activities, museums, gyms, schools and universities. The unvaccinated will effectively be barred from entering any business in the city except for supermarkets and pharmacies.
Abu Dhabi has already rolled out a “green pass” system that limits public access to those who have either received the shot or can show a negative virus test.
It comes as the country increasingly bets its economic reopening on its speedy vaccination campaign. The government says at least 93% of Abu Dhabi’s population has received at least one dose of the vaccine.
The neighboring travel hub of Dubai, home to long-haul carrier Emirates, also has introduced some vaccination restrictions on mass entertainment and sporting events. However, malls and other businesses remain open to the unvaccinated.
The UAE boasts one of the world’s fastest inoculation campaigns, with 15.1 million doses administered to its population of some 9 million. The country has relied heavily on the Chinese state-backed Sinopharm shot.
Yes, let's 'encourage' people to get their shots. (93 percent is not enough! ) But surely we'll never get to the point where we search out individuals to make sure no one is left behind, will we? Nah ...
Display MoreSome more Covid news from Canada.
My city of Toronto has set a world record. On Sunday we opened up the Air Canada Centre (now called ScotiaBank Centre where the Toronto Maple Leafs and Toronto Raptors play), and amid lots of fanfare we vaccinated over 26,000 people. That's the most ever in one place in one day, worldwide.
Have to hand it to those who came up with this idea. Keep people out of popular sports venues for over a year, and then open the floodgates for a one time celebratory mass vaccination event! Genius.
***********
Some researchers were suspicious of Canada's exceptionally high proportion of covid deaths in long term care homes relative to overall covid deaths : 80 percent. They now write that Covid deaths outside of care homes have been under reported by at least 66 percent! If this under reporting has continued to the present, it means that reported Canada's Covid deaths may be half of the real number. Close enough for government work?
This has been the problem in many places. Mexico, Peru and Brazil had excess mortalities up to 400% and the official Covid death toll explains at best 50% of it and at worst 30% (Peru had this problem, also Ecuador probably has not been able to record even 10% of the deaths at some critical points). Even my country has about a 20% discrepancy.
But the risk of dying from Covid-19 is extraordinarily dependent on age: it halves for each six to seven year age gap. This means that someone aged 80 who is fully vaccinated essentially takes on the risk of an unvaccinated person of around 50 – much lower, but still not nothing, and so we can expect some deaths.
This is an absolutely fringe excuse!! Fake!
Just look at deaths among age >65 before and after delta!! That is all you need to do!
Younger people do not need the vaccine! The vaccine should protect the old and does not!!
This is absolute worrisome news as it is confirmed by Israel data. Is this just the beginning of a negative vaccine effect?
Anyway: The true criminal fact is: Nobody must die if Ivermectin would be prescribed.
The vaccines are not perfect. PHE estimates two-dose effectiveness against hospital admission with the Delta infections at around 94%
This figure (94%) has never been confirmed. CDC gave 89%. But it looks like for older people it is far less. May be just 70% or even lower.
Further we know that even in the worst affected care homes 50% of the people did not get CoV-19. So also among older we have the well known 80% people (average!) that have enough immunity without the vaccine. So for statistics about protection from death you must compare only the 20% that did get an added protection.
So with 90% vaccination among age >65 you in fact should get get 98% total protection.With 30% (vaccinated) among younger this figure is only 86%. This gives you the high risk pool size of potential victims 2% for old 14% for young.
Then - in the analysis you have to adjust the death with the pool size. (death/"pool size")
This is true statistics based on medical facts not fake big pharma propaganda.
If you adjust the vaccine protection before you construct the pool size then you get fake data. We also have no separate data for death protection alone.
E.g. for 95% vaccine protection the old pool of vulnerable would increase to 3% the younger would be 15%. If you do the proper adjustment for the vaccine protection .
Just to repeat it again: 80% have natural immunity! Here vaccine ads nothing!
Lisbon court rules only 0.9% of 'verified cases' died of COVID, numbering 152, not 17,000 claimed.
Here are the court documents the article is based on. The severity of pandemics of coronavirus in Spain and Portugal significantly differ just by application of vaccines in populations, which are otherwise quite similar. GMO free Portuguese had no problems with coronavirus with compare to neighbouring Spain, for example..
One possible contributing factor is the historic adoption of the BCG (Baccillus-C-G) vaccine against Tuberculosis 1, 2. A good example of this is looking at Spain and Portugal by a recent analysis. Although Spain does not practice the BCG vaccine, Portugal does. While Spain had the 2nd highest rates of coronavirus cases and corresponding deaths in the world (at 140,511 and 13,897 respectively as of April 7th 2020), Portugal has just 12,442 cases and 345 deaths. This comes despite the proximity of the two countries on the Iberian peninsula. See also:
The Safety of COVID-19 Vaccinations—We Should Rethink the Policy
https://www.mdpi.com/2076-393X/9/7/693/htm
One more top gun shot: https://americasfrontlinedocto…t-checker-a-pack-of-lies/
The Safety of COVID-19 Vaccinations—We Should Rethink the Policy
I uploaded it yesterday to keep it alive . one page back!
I uploaded it yesterday to keep it alive . one page back!
And I linked it even before that! But is not a contest, this thread is hard to keep up with.
And now at least the Pfizer Comirnaty vax is confirmed to have Graphene flakes, which are not listed anywhere in the ingredients list.
